Pharma Faces Phase III Licensing Drought; Separate R&D “Pools” May Help
Pharmaceutical companies should separate R&D budgets for internal and external deals, Bayer Licensing & Acquisitions Associate Director Ann Kraft suggested
Pharmaceutical companies should separate R&D budgets for internal and external deals, Bayer Licensing & Acquisitions Associate Director Ann Kraft suggested